




January 2010

Volume 15 · Numbers 1/2

pp. 1–80



Cover Story

The featured review in this issue of *Drug Discovery Today*, by S.J. Campbell, A. Gaulton, J. Marshall, D. Bichko, S. Martin, C. Brouwer and L. Harland, discusses how the lack of integration between chemical, biological and clinical information sources hinders the development of a holistic vision of the drug discovery landscape and hence makes therapeutic hypothesis generation less precise. The authors review systems capable of handling diverse data sets and highlight the use of visualization to enhance the process. They argue the need for more tools in this space and the role that data standards, new technologies and increased collaboration might have in achieving this aim.

DRUG DISCOVERY TODAY

REVIEWS

KEYNOTE

3 Visualizing the drug target landscape

Stephen J. Campbell, Anna Gaulton, Jason Marshall, Dmitri Bichko, Sid Martin, Cory Brouwer and Lee Harland

INFORMATICS

16 Computational toxicology—a tool for early safety evaluation

Cédric Merlot

23 Molecular fields in drug discovery: getting old or reaching maturity?

Simon Cross and Gabriele Cruciani

GENE TO SCREEN

33 Mitochondrial pharmacogenomics: barcode for antibiotic therapy

David Pacheu-Grau, Aurora Gómez-Durán, Manuel J. López-Pérez, Julio Montoya and Eduardo Ruiz-Pesini

POST SCREEN

40 Synthetic therapeutic peptides: science and market

Patrick Vlieghe, Vincent Lisowski, Jean Martinez and Michel Khrestchatisky

57 Cyclotides as templates in drug design

Sónia Troeira Henriques and David J. Craik

65 Epigenetic opportunities and challenges in cancer

Jonathan D. Best and Nessa Carey

71 Biologics and postbiologics: novel immunotherapeutics for the induction and maintenance of remission

Willem van Eden, Jeffrey Lisse, Berent Prakken and Salvatore Albani

DRUG DISCOVERY TODAY**Editorial**

Editor: Steve Carney
Assistant Editor: Kirsty Strawbridge
Content Development Manager: Joanna Aldred
Journal Manager: Basil Nyaku
Publisher: Jaap van Harten
Editorial Enquiries:
Drug Discovery Today
 Elsevier
 32 Jamestown Road, London, NW1 7BY, UK
 Tel: +44 (0)20 7424 4200
 Fax: +44 (0)1865 853067
 Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD

Jurgen Bajorath *University of Bonn, Germany*
Walter Blackstock *Experimental Therapeutics Centre, Singapore*
David Brayden *University College Dublin, Ireland*
Paul Caron *Vertex Pharmaceuticals, USA*
David Cavalla *Arachnova, UK*
David Clark *Argenta Discovery, UK*
Dalia Cohen *Rosetta Genomics, USA*
Donald Daley *Argenta Discovery, UK*
Sean Ekins *ACT LLC and Collaborations in Chemistry, USA*
Hans-Peter Fischer *GeneData, Switzerland*
Peter Ghazal *University of Edinburgh, UK*
Christopher M. Hill *Organon, UK*
Nick Hird *Takeda Chemical Industries, Japan*
Enoch Huang *Pfizer, USA*
Thomas Joos *University of Tuebingen, Germany*
Vincent H.L. Lee *Chinese University of Hong Kong, Hong Kong*
David Lewin *Yale University, USA*
Christopher A. Lipinski *Meliior Discovery, USA*
Lorenz Mayr *Novartis, Switzerland*
Nick Meanwell *Bristol-Myers Squibb, USA*
BK Muralidhara *Pfizer Global Biologics, St. Louis, USA*
Mark Murcko *Vertex Pharmaceuticals, USA*
Fajun Nan *Shanghai Institute of Materia Medica, China*
Pradeep Nathan *Experimental Medicine, GSK and University of Cambridge*
Gitte Neubauer *Cellzome, Germany*
Eric Neumann *Teranode, USA*
Tim Peakman *UK Biobank, UK*
Norton Peet *Aurigene, USA*
Manuel Peitsch *Novartis, Switzerland*
Kurt Rasmussen *Eli Lilly and Co. Ltd. USA*
Janice Reichert *Tufts Center for the Study of Drug Development, USA*
John Reidhaar-Olson *Hoffmann-La Roche, USA*
Mike Romanos *GlaxoSmithKline, UK*
Raymond C. Rowe *Intelligensys, UK*
Andreas Russ *University of Oxford, UK*
Esther Schmid *Pfizer, UK*
Jonathan Sheldon *Inforsense, UK*
Michael Snyder *Yale University, USA*
Susie Stephens *Eli Lilly and Co. Ltd., USA*
Robert Strausberg *The J. Craig Venter Institute, USA*
Donny Strosberg *Scripps Florida, USA*
Yuichi Sugiyama *University of Tokyo, Japan*
David Szymkowski *Xencor, USA*
Nick Terrett *Ensemble Discovery, USA*
Vladimir Torchilin *Northeastern University, Boston, USA*
Mark Whittaker *Evotec OAI, UK*
Hans Winkler *Johnson and Johnson, Belgium*
Limsoon Wong *Laboratories for Information Technology (LIT), Singapore*
X.F. Steven Zheng *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

EDITORIAL

- 1 The shrinking of the knowledge base – what is the impact of this on the speed and security of drug development?**

Paul Branthwaite

ERRATUM

- 78 Orally bioavailable proteasome inhibitors: preclinical development of PR-047**

MONITOR

- 79 Discovery of PDE10A inhibitor, PF-2545920**

Michael A. Walker

- 80 DIARY**

FORTHCOMING ARTICLES:**CAN MOLECULAR BIOMARKER-BASED PATIENT SELECTION IN PHASE I TRIALS ACCELERATE ANTICANCER DRUG DEVELOPMENT?**

By Craig P. Carden, Debashis Sarker, Sophie Postel-Vinay, Timothy A. Yap, Gerthardt Attard, Udai Banerji, Michelle D. Garrett, George V. Thomas, Paul Workman, Stan B. Kaye and Johann S. de Bono

FROM BIOMARKER STRATEGIES TO BIOMARKER ACTIVITIES, AND BACK

By Alain J. van Gool, Brian Henry and Erik D. Sprengers

CIRCULATING PREDICTIVE BIOMARKERS IN ONCOLOGY

By Darren R. Hodgson, Robert Wellings, Maria C.M. Orr, Rose McCormack, Michael Malone, Ruth E. Board and Mireille V. Cantarini

RECENT ADVANCES IN CANCER PROGRESSION IMAGING BIOMARKERS: APPLICATION OF BENCH TO BEDSIDE TECHNOLOGIES

By Roy van der Meel, William M. Gallagher, Sabrina Oliveira, Aisling E. O'Connor, Raymond Schiffelers and Annette T. Byrne